Latest news with #NarayanaHrudayalaya
&w=3840&q=100)
Business Standard
7 days ago
- Business
- Business Standard
Breakout stocks: KNR Cons, Apar, NH and 2 others may see up to 23% upside
Kirsloskar Brothers, EID Parry and Narayana Hrudayalaya among 5 stocks trading above the higher-end of the Bollinger Bands, thus indicating a technical breakout on the daily charts. Rex Cano Mumbai Listen to This Article Kirloskar Brothers, EID Parry, KNR Construction, Apar Industries and Narayana Hrudayalaya have witnessed a breakout on the daily chart on Thursday, June 26, 2025. All these 5 stocks are seen trading above the higher-end of the Bollinger Bands on the respective daily charts. In technical terms, the Bollinger Bands are used to identify anticipated trading range and potential trend reversals and breakout. In general, stocks trading above the higher-end of the Bollinger Bands are considered bullish, and vice versa. However, other key technical indicators such as the moving averages and momentum oscillators also play a crucial part.
&w=3840&q=100)
Business Standard
13-06-2025
- Business
- Business Standard
Narayana, Max Healthcare shares gain up to 5%, hit new highs in weak market
Shares of hospitals and healthcare services providers were in demand, and rallied up to 5 per cent on the BSE in Friday's intra-day trade in an otherwise weak market on the back of a healthy outlook. Shares of Narayana Hrudayalaya hit a new high of ₹1,906.15, surging 5 per cent on the BSE in intra-day trade. The stock surpassed its previous high of ₹1,872.85 touched on April 21, 2025. The share price of Max Healthcare Institute also hit a new high of ₹1,234.70, gaining 3 per cent in intra-day trade. It surpassed its earlier high of ₹1,227.50 touched on January 8, 2025. Thyrocare Technologies (up 5 per cent at ₹1,028.90) and Krishna Institute of Medical Sciences or KIMS (up 3 per cent at ₹683.05) were up in the range of 3 per cent and 5 per cent. In comparison, the BSE Sensex was down 0.73 per cent at 81,096 at 02:01 PM. Most Indian hospitals have now broken even and started contributing to profits. There is a rising demand for specialized treatments, including oncology and high-end surgical procedures. This trend is contributing to higher ARPOB (Average Revenue per Occupied Bed) and overall revenue growth. According to analysts at Choice Equity Broking, accounting for ~5-7 per cent of revenue, medical tourism is expected to grow at nearly double the overall rate in the mid-term. Factors such as normalization in the geo-political issue, operationalization of a new airport in Noida, affordable treatment costs, world-class facilities, and skilled medical personnel will continue to attract international patients, particularly from Southeast Asia and the Middle East, analysts said. Meanwhile, India's healthcare sector is on the cusp of significant transformation, driven by increased public and private investments, policy initiatives, and demographic shifts. Despite the current challenges, including disparities in healthcare infrastructure and the availability of medical services in the workforce between urban and rural areas, the future looks promising with sustained efforts and strategic investments. As of 2022, India's healthcare spending accounted for 3.3 per cent of the GDP; however, with sustained efforts, it is anticipated to reach 5 per cent by 2030, according to CareEdge Ratings. Looking forward, the rising share of the population aged over 45 years, coupled with income growth, is also expected to catalyse higher demand for quality healthcare services. This demand will likely translate into sustained investments across the entire value chain, from medical education and training to hospital infrastructure and digital healthcare technologies, the rating agency said. As per latest available data from National Health Accounts (NHA), government healthcare spending has increased significantly in recent years. The government health expenditure (GHE) as a percentage of GDP grew from ~1.1 per cent in FY15 to ~1.8 per cent in FY22. Similarly, its share within the general government expenditure (GGE) saw a notable rise, climbing from ~3.9 per cent in FY15 to ~6.1 per cent in FY22. GHE as a percentage of total health expenditure (THE) grew from 40.8 per cent in FY18 to 48.0 per cent in FY22, demonstrating a shift toward government-funded healthcare. These trends highlight the government's growing commitment to strengthening the healthcare sector. Furthermore, per capita government health expenditure rose from ₹ 1,753 in FY18 to ₹ 3,169 in FY22 at a 16 per cent CAGR, indicating increased spending on healthcare services per individual, analysts at Elara Capital said in the Health Insurance sector update.
Business Upturn
29-05-2025
- Business
- Business Upturn
HSBC maintains reduce on Narayana Hrudayalaya, sees long gestation for India expansion
By News Desk Published on May 29, 2025, 07:56 IST HSBC has maintained a Reduce rating on Narayana Hrudayalaya with a target price of ₹1,220, even as the company posted an operational beat in Q4FY25, mainly driven by stronger-than-expected performance from its new Cayman Islands unit. The brokerage highlighted that while the Q4 numbers exceeded their expectations, the key driver was the Cayman facility, which ramped up ahead of schedule. However, HSBC remained cautious on the medium-term growth outlook, pointing out that the benefits from Narayana's ongoing bed expansion in India are still 3–4 years away. The firm believes that while the current momentum is encouraging, valuations already factor in much of the near-term optimism, and the long gestation period for Indian operations tempers their overall outlook. Disclaimer: The views and recommendations expressed above are those of the respective brokerage firm. Business Upturn does not endorse or offer any investment advice. News desk at
Yahoo
28-05-2025
- Business
- Yahoo
Narayana Hrudayalaya Ltd (BOM:539551) Q4 2025 Earnings Call Highlights: Strong Cayman Growth ...
Release Date: May 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Narayana Hrudayalaya Ltd (BOM:539551) has seen strong growth in its Cayman business, with new departments like urgent care and women's health contributing positively. The company has achieved a 45% margin in its Cayman operations, indicating strong financial performance. Narayana Hrudayalaya Ltd (BOM:539551) is focusing on organic growth through improved throughput and higher order procedures, which has sustained growth without adding new capacity. The company has a strong technology platform that enhances operational efficiency, allowing it to perform tasks with fewer resources. Narayana Hrudayalaya Ltd (BOM:539551) has a low debt-to-equity ratio, providing significant headroom for future borrowing if needed. The Indian business faces challenges with clinic and insurance losses, which are expected to grow as the company expands its clinic portfolio. There is a temporary increase in working capital days due to delayed payments from government payers, impacting cash flow. The company is experiencing a decline in international patient revenue, particularly from Bangladesh, which may continue to decrease. Narayana Hrudayalaya Ltd (BOM:539551) has not added significant new bed capacity in recent years, which may limit growth potential until new facilities are operational. The company faces challenges in retaining high-quality staff due to increasing competition in the healthcare sector. Warning! GuruFocus has detected 5 Warning Signs with KUASF. Q: Can you provide some color on the Cayman business growth and whether $45 million will be the new base for revenue? A: The hospital has been well-received, with new departments like urgent care and women's health contributing to growth. While there may be fluctuations, $45 million is a good base assumption for sustainable revenue. (Unidentified_3) Q: With Cayman margins at 45%, is there potential for further improvement, or will the focus shift to revenue growth? A: Beyond this point, focusing on improving margins at the expense of revenue growth doesn't make sense. The goal is now revenue growth, as crossing this margin level would be challenging and not sensible long-term. (Unidentified_3) Q: Regarding the Indian business, are the clinic and insurance losses at their peak, or could they extend further? A: The losses will grow due to expansion plans for clinics, but over 3-4 years, we aim to stay within a set investment horizon. The current cash burn is due to initial costs in new clinics and cities. (Unidentified_4) Q: What is the strategy for growth before the greenfield expansion kicks in? A: We will sustain growth through throughput initiatives, as seen in past years without adding capacity. We aspire to maintain the growth momentum without providing forward guidance. (Unidentified_4) Q: Can you elaborate on the insurance business and its reception among patients? A: Customers have responded positively, with about 4,000 lives covered. We focus on high-quality underwriting and risk management, providing an exceptional claims experience. Our strategy is to build distribution and expand to more markets. (Unidentified_6) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Business Standard
26-05-2025
- Business
- Business Standard
Narayana Hrudayalaya surges after Q4 PAT rises 3% YoY to Rs 197 cr
Narayana Hrudayalaya rallied 8.44% to Rs 1,870 after the company reported a 3.41% rise in consolidated net profit to Rs 197.21 crore on an 18.39% increase in revenue from operations to Rs 1,475.44 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 253.02 crore during the quarter, registering a growth of 13.86% from Rs 222.22 crore reported in Q4 FY24. India's revenue stood at Rs 1,108.8 crore, up 10.66% year-on-year (YoY), while revenue from the Cayman Islands was Rs 379.7 crore, up 50.2% YoY. Consolidated EBITDA grew by 22.17% to Rs 384.6 crore in the March 2025 quarter from Rs 314.8 crore in Q4 FY24. EBITDA margin improved to 26.1% in Q4 FY25 as against 25.3% in Q4 FY24. On the margins front, the company's operating margin reduced to 24.25% in Q4 FY25, compared with 23.02% recorded in Q4 FY24. Net profit margin declined to 13.30% in Q4 FY25 from 14.91% registered in Q4 FY24. As of March 31, 2025, the companys total borrowings, net of cash, bank balances, and current investments, stood at Rs 533 crore. The net debt-to-equity ratio was at 0.15, with foreign currency-denominated debt amounting to $86.8 million. On a full-year basis, the company's net profit rose 0.11% to Rs 790.16 crore on a 12.12% rise in revenue to Rs 5,482.98 crore in FY25 over FY24. Dr. Emmanuel Rupert, managing director and group CEO, Narayana Hrudayalaya, said, The current financial year demonstrated strong performance across our units, both domestic and international; we are pleased to report the highest-ever revenues and profitability margins on both a quarterly and an annual basis at the consolidated level. The performance improvement in India units has been driven by domestic volume pickup, increased realizations, and optimization in payor categories. While our flagships continue to contribute significantly, our Southern Peripheral and North units have shown significant growth this year, and we hope to build on the momentum going forward. The new hospital in Camana Bay is fully functional and is contributing meaningfully to the overall Cayman business. We are excited about the traction in the new hospital and are confident that the region will deliver strong growth going forward. The integrated care business is picking up well, with our new clinics garnering sizeable footfalls. We will continue to invest in this business and are optimistic that it will be a significant driver of growth for the overall NH ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the upcoming year. Meanwhile, the board has recommended a final dividend of Rs 4.50 per equity share for the financial year ended March 31, 2025. The record date for determining eligible shareholders has been set as Friday, 1 August 2025. Additionally, the board approved a proposal to seek shareholder approval via special resolution to raise up to Rs 1,500 crore in a financial year through the issuance of debt securities, including non-convertible debentures (NCDs), in one or more tranches on a private placement basis. The securities may be denominated in Indian rupees or foreign currency. Narayana Hrudayalaya is one of the leading healthcare service providers in India, operating a chain of multispecialty, tertiary, and primary healthcare facilities. The company has a network of 18 hospitals and 2 heart centers across India, along with an overseas presence in the Cayman Islands, with over 5,550 operational beds and a capacity of over 5,900 beds.
